Premier purchases developer of corneal system:
This article was originally published in Clinica
Premier Laser Systems is buying EyeSys Technologies, a privately-held developer of corneal topography systems which has 3,500 systems installed worldwide. Premier will pay $10.6 million worth of stock for EyeSys in the deal which is expected to be completed by the end of June. The chief executive of Premier, Colette Cozean, said it plans to use EyeSys' marketing network to sell its own ophthalmic lasers. The acquisition is the culmination of Premier's strategy to acquire companies with strong international and US distribution channels. EyeSys had sales of about $8 million last year.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.